---
title: "WuXi AppTec Presents Research Platforms Supporting Integrated CRDMO Model"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306264597.md"
description: "WuXi AppTec outlined plans to expand automated research capabilities and strengthen its integrated CRDMO model at its Investor Day. Key highlights include targeting full ADME automation in Nanjing by end-2026 with a capacity of up to 200 plates daily, reporting a 28% year-over-year rise in non-cancer in vivo pharmacology revenue for H1 2026, and noting that customers using both discovery and preclinical platforms accounted for 77.8% of 2025 revenue."
datetime: "2026-11-20T11:05:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306264597.md)
  - [en](https://longbridge.com/en/news/306264597.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306264597.md)
generator: "portal-rs"
---

# WuXi AppTec Presents Research Platforms Supporting Integrated CRDMO Model

-   WuXi AppTec outlined plans to expand automated research capabilities and strengthen its integrated research, development and manufacturing model at its Investor Day. \* Full ADME automation in Nanjing is targeted for completion by the end of 2026, with capacity of up to 200 plates daily. \* Non-cancer in vivo pharmacology revenue rose 28% year over year in the first half of 2026. \* Customers using both discovery and preclinical platforms accounted for 77.8% of revenue in 2025, up from 74.4% in 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)

## Related News & Research

- [WuXi AppTec Expects 2026 Chemistry Revenue of RMB 52.8 Billion-53.5 Billion](https://longbridge.com/en/news/306264750.md)
- [WuXi AppTec Co., Ltd. Raises FY26 Guidance After Strong Q1–Q3](https://longbridge.com/en/news/303058517.md)
- [Citi: Removal of WUXI APPTEC from US 1260H List a Major Positive](https://longbridge.com/en/news/304953763.md)
- [WuXi AppTec Non-GAAP EPS of RMB 6.21, revenue of RMB 45.54B; rasies full-year guidance](https://longbridge.com/en/news/303068409.md)
- [G Sachs: WUXI APPTEC  3Q Results Solid, Raises Guidance Again; Visibility for Growth Next Year Improves](https://longbridge.com/en/news/303169062.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**